Abivax S.A. (AAVXF) — 6-K Filings

6-K Filings (24)

• 6-K Filing — Dec 15, 2025
• Abivax S.A. Files 6-K for H1 2025 Financials — Sep 8, 2025 Risk: low
  Abivax S.A. filed a 6-K report for the period ending June 30, 2025. The filing includes financial data for the first half of 2025 and the full year 2024, detail
• Abivax SA Enters Underwriting Agreement for Securities Sale — Jul 24, 2025 Risk: medium
  On July 23, 2025, Abivax SA entered into an Underwriting Agreement with Leerink Partners LLC, Piper Sandler & Co., and Guggenheim Securities, LLC, acting as rep
• Abivax SA Announces Positive Phase 3 UC Trial Results — Jul 22, 2025 Risk: medium
  On July 22, 2025, Abivax SA announced positive Phase 3 results for its drug obefazimod in moderate to severely active ulcerative colitis (UC). The ABTECT-1 and
• Abivax SA Shareholder Meeting Results Confirmed — Jun 11, 2025 Risk: low
  Abivax S.A. held its ordinary and extraordinary general meeting of shareholders on June 6, 2025. The meeting confirmed the final results of several agenda items
• Abivax S.A. Q1 2025 Financials Filed — Jun 2, 2025 Risk: low
  Abivax S.A. filed a 6-K report for the period ending March 31, 2025. The filing includes financial data for the first quarter of 2025, with comparative figures
• Abivax Completes Enrollment for Ulcerative Colitis Phase 3 Trials — Apr 29, 2025 Risk: medium
  On April 29, 2025, Abivax SA announced the completion of patient enrollment for its Phase 3 ABTECT trials. These trials are investigating the efficacy of obefaz
• Abivax Announces AGM Details and Board Appointment — Apr 22, 2025 Risk: low
  On April 22, 2025, Abivax SA announced details for its Annual General Meeting, highlighting the company's progress towards significant 2025 value-driving milest
• Abivax Obefazimod Trial Data Published in The Lancet — Jan 10, 2025 Risk: medium
  On January 9, 2025, Abivax SA announced the publication of positive Phase 2b clinical trial results for its lead drug candidate, obefazimod, in the journal 'The
• Abivax SA Director Resigns — Dec 23, 2024 Risk: low
  On December 23, 2024, Abivax SA announced that Dr. Philippe Pouletty will resign from its Board of Directors, effective December 31, 2024. This resignation is n
• Abivax SA Establishes Equity Offering Program with Piper Sandler — Nov 19, 2024 Risk: medium
  On November 19, 2024, Abivax SA entered into an Equity Distribution Agreement with Piper Sandler & Co. to establish an equity offering program. Under this progr
• Abivax SA Files Key Financials as of Q3 2024 — Nov 14, 2024 Risk: low
  Abivax SA announced key financial information as of September 30, 2024, via a press release filed on November 14, 2024. This preliminary financial data is the r
• Abivax Files 6-K, Reports Foreign Issuer Status — Oct 3, 2024 Risk: low
  Abivax S.A. filed a Form 6-K on October 3, 2024, reporting its status as a foreign private issuer. The company, based in Paris, France, is registered with the S
• Abivax Files September 2024 6-K Report — Sep 26, 2024 Risk: low
  Abivax S.A. filed a Form 6-K on September 26, 2024, reporting for the month of September 2024. The filing indicates that Abivax is a foreign private issuer and
• Abivax Files September 2024 6-K Report — Sep 25, 2024 Risk: low
  Abivax S.A. filed a Form 6-K on September 25, 2024, to report its activities for the month of September 2024. The filing indicates that Abivax is a foreign priv
• Abivax Files September 2024 6-K Report — Sep 9, 2024 Risk: low
  Abivax S.A. filed a Form 6-K on September 9, 2024, reporting for the month of September 2024. The company, based in Paris, France, is a pharmaceutical preparati
• Abivax SA Files Q2 2024 Financial Results — Sep 9, 2024 Risk: low
  On September 9, 2024, Abivax SA filed a Form 6-K to report its financial results for the six months ended June 30, 2024. This filing includes a press release an
• Abivax Files August 2024 6-K Report — Aug 6, 2024 Risk: low
  Abivax S.A. filed a Form 6-K on August 6, 2024, reporting for the month of August 2024. The company, based in Paris, France, is a pharmaceutical preparations co
• Abivax Files July 2024 6-K Report — Jul 16, 2024 Risk: low
  Abivax S.A. filed a Form 6-K on July 16, 2024, reporting for the month of July 2024. The company, based in Paris, France, is a pharmaceutical preparations compa
• Abivax SA Shareholder Meeting Results Announced — Jun 4, 2024 Risk: low
  On May 30, 2024, Abivax SA held its ordinary and extraordinary general meeting of shareholders. Out of 61,012,501 shares with voting rights, 49,815,120 shares w
• Abivax Files 6-K, Confirms 20-F Reporting — May 7, 2024 Risk: low
  Abivax S.A. filed a Form 6-K on May 7, 2024, reporting its status as a foreign private issuer. The filing confirms Abivax is submitting its annual reports under
• Abivax Files April 2024 Report on Form 6-K — Apr 2, 2024 Risk: low
  Abivax S.A. filed a Form 6-K on April 2, 2024, to report its activities for the month of April 2024. The filing indicates that Abivax is a foreign private issue
• Abivax Files 6-K, Attaches Feb 2 Press Release as Exhibit 99.1 — Feb 2, 2024
  Abivax S.A., a pharmaceutical company, filed a 6-K on February 2, 2024, indicating they issued a press release on the same date. This filing, under Commission F
• Abivax Files 6-K, Signals Press Release Issued Jan 22, 2024 — Jan 22, 2024
  Abivax S.A., a pharmaceutical company, filed a 6-K on January 22, 2024, indicating they issued a press release on the same date. This filing itself doesn't cont

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX